Tagged with Global

Global Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.   As pharma companies gear up for another year – a year that marks a quarter of the way through…

Global With a record number of recent approvals representing game-changing potential for conditions like sickle cell disease, a significant number of advanced therapies making progress in the clinic, and an uptick in investment, cell and gene therapies are set to continue making considerable headway in 2025. Yet their elevated price tag…

Global Throughout the year PharmaBoardroom has talked to pharma and biotech executives and life sciences opinion leaders across the globe, gathering vital insights into local markets, learning about promising new therapies, and examining the broader trends shaping the industry. Here is a selection of some of the year’s most-read interviews.  …

Europe Jazz Pharmaceuticals is about to open a new chapter in its history. As long-standing CEO and co-founder Bruce Cozadd prepares to step down for retirement, the neuroscience and oncology-focused company begins its search for a new leader and gets ready to commercialize recently FDA-approved HER2-targeted bispecific antibody, Ziihera.    End…

Switzerland Switzerland has a vital role to play in global health, especially in the world’s poorest countries. Indisputably the global capital for health and humanitarian work, its political neutrality, central European location, economic stability, and quality of life have helped foster a dense network of UN agencies, NGOs, and private sector…

Global IFPMA represents the innovative pharmaceutical industry at the international level and in official relations with the United Nations. Dr David Reddy joined the association earlier this year, and shares his analysis on how vaccines and treatments are transforming health outcomes for people around the world, and how the pipeline of…

Global Scott D. Ramsey of the Fred Hutchinson Cancer Center discusses the trend driving pharmaceutical companies to reorganize or eliminate their health economics and outcomes research (HEOR) groups. The original version of this article was featured in the September/October edition of ISPOR’s Value & Outcomes Spotlight magazine.   Last spring, I had…

Switzerland This interview explores the transformative journey of Tillotts Pharma under the leadership of CEO Thomas Tóth von Kiskér, who has guided the company from a small team in 1996 to a global player with a focus on in-house R&D, strategic M&A, and a commitment to patient-centric innovation. Priorities for continued…

Global With the emergence of GLP-1 RA therapies the obesity drug market has taken off and stands to be worth some USD 125.3 billion by 2033. Eli Lilly and Novo Nordisk may lead the charge, but other contenders are looking to get a piece of this lucrative market as the two…

Global Dr Catherine Duggan, CEO of the International Pharmaceutical Federation, lays out how mental health systems must shift from reactive crisis intervention to proactive, patient-centered approaches; why traditional care models need reimagined funding that prioritises community mental health services and incentivises innovation; and the vital role that pharmacists, as accessible healthcare…

Global In conversation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 in Madrid, Roche Diagnostics’ Margherita Carboni discusses the potential of blood-based biomarkers to transform Alzheimer’s diagnostics, offering a faster and less invasive alternative to traditional methods. She highlights Roche’s commitment to ensuring diversity in clinical trials, a crucial step in…

Global The 2024 Access to Medicine Index, released today, highlights some of the key milestones reached by global pharma in fostering access to their medicines in low- and middle-income countries (LMICs). Novartis tops the ranking – based on a wide-ranging assessment of access governance, R&D, and product delivery – meaning that…